Effects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease

Statatic and Dynamic Balance (Mini Balance Evaluation Systems Test - MiniBESTest)

Balance will be evaluated using the Mini Balance Evaluation Systems Test (Mini-BESTest), a validated tool for individuals with Parkinson's disease. The test includes 14 items covering anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. Each item is scored on a 3-point ordinal scale, with a total score ranging from 0 to 28. Higher scores indicate better balance.

Time frame: Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention

Motor function (Movement Disorder Society-Unified Parkinson's Disease Rating Scale - MDS-UPDRS)

Motor function will be assessed using Sections II (Activities of Daily Living) and III (Motor Examination) of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Items are scored from 0 (normal) to 4 (severe), with lower scores indicating better motor function.

Time frame: Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention

Freezing of gait (Freezing of gait Questionnaire - FOG-Q)

Freezing of gait will be assessed using the Freezing of Gait Questionnaire (FOG-Q), a patient-reported measure that evaluates the severity and functional impact of freezing episodes during walking. Total scores range from 0 to 24, with higher scores indicating greater impairment.

Time frame: Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention

Gait speed (10 meter-walk test)

Gait speed will be measured using the 10-Meter Walk Test. Participants will walk at usual and fastest safe speeds. Time will be recorded and converted to meters per second (m/s).

Time frame: Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention

Lower limb stength (Five times sit-to-stand test)

Lower limb strength will be assessed using the Five Times Sit-to-Stand Test (5xSTS). The time to complete five repetitions will be recorded in seconds, with longer times indicating poorer performance.

Time frame: Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention

Quality of Life Measured by the Parkinson's Disease Questionnaire-39 (PDQ-39): Total Score and Domain Scores

Quality of life will be evaluated using the Parkinson's Disease Questionnaire-39 (PDQ-39). Scores range from 0 to 100, with higher scores indicating worse quality of life. Both total and domain scores will be analyzed.

Time frame: Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention

Global Perceived Improvement (Global perceived change scale)

Global perceived improvement will be assessed using the Global Perceived Change scale, a 7-point patient-reported measure ranging from "no change" to "much better."

Time frame: At Day 10 (end of intervention)

Adverse events

Adverse events will be monitored using a standardized questionnaire for magnetic stimulation-related side effects, including headache, scalp discomfort, tingling, fatigue, nausea, and drowsiness, rated from 0 (none) to 4 (severe).

Time frame: Throughout the intervention period (10 days)